Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study

被引:9
|
作者
Moehler, M
Gutzler, F
Steinmann, S
Boehme, M
Raeth, U
Stremmel, W
Galle, PR
Rudi, J
机构
[1] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany
[2] Heidelberg Univ, Dept Med 4, Heidelberg, Germany
关键词
metastatic colorectal cancer; chemotherapy; folinic acid; continuous infusion; 5-fluorouracil;
D O I
10.1159/000069778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC). Consequently, we compared toxicity, response and survival following two FA/5-FU regimens in 55 CRC patients refractory to bolus FA/5-FU. Methods: Twenty-eight patients (group A) received 54:U (60 mg/kg body weight) for 48 h, and 27 (group B) received 2-hour infusions of FA (500 mg/m(2)) and 24-hour infusions of 5-FU (2,600 mg/m(2)) until disease progression. Results: Both groups were adequately matched with respect to patient characteristics. While overall toxicities were rare, hand-foot syndrome was more common in A. Tumor control was achieved in 57 and 44%, for A and B, respectively. Survival times were 16 months in A and 9 months in B. Conclusions: Since both 5-FU infusion protocols showed equivalent palliative effects, FA may be questioned in second-line 5-FU regimens. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [1] Paclitaxel and weekly 24-hour infusion of 5-fluorouracil folinic acid in advanced gastric cancer
    Bokemeyer, C
    Hartmann, JT
    Lampe, CS
    Clemens, MR
    Quietzsch, D
    Forkmann, L
    Kanz, L
    SEMINARS IN ONCOLOGY, 1997, 24 (06) : S96 - S100
  • [2] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [3] Topotecan or a weekly 24-hour infusion in patients with advanced colorectal cancer pretreated with 5-fluorouracil/folinic acid.
    Quietzsch, D
    Baronius, W
    Jungberg, P
    Liebert, A
    TUMORDIAGNOSTIK & THERAPIE, 2000, 21 (03) : 68 - 75
  • [4] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [5] Weekly high-dose 5-fluorouracil 24-hour infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer
    Stoffregen, C
    Zurborn, KH
    Boehme, V
    Schmid, A
    Lorenz, G
    Arendt, T
    Folsch, UR
    ONKOLOGIE, 1996, 19 (05): : 410 - 414
  • [6] Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer
    Sandor, V
    LANCET, 1997, 350 (9087): : 1325 - 1326
  • [7] FOLINIC ACID, 5-FLUOROURACIL BOLUS AND INFUSION AND MITOXANTRONE WITH OR WITHOUT CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER
    LOUVET, C
    DEGRAMONT, A
    DEMUYNCK, B
    BEERBLOCK, K
    VARETTE, C
    SOUBRANE, D
    MARPEAU, L
    PIGNE, A
    GUILLOT, T
    KRULIK, M
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) : 1835 - 1838
  • [8] CONTINUOUS INFUSION 5-FLUOROURACIL AND FOLINIC ACID IN DISSEMINATED COLORECTAL-CANCER
    MORTIMER, JE
    HIGANO, C
    CANCER INVESTIGATION, 1988, 6 (02) : 129 - 132
  • [9] 5-FLUOROURACIL AND FOLINIC ACID IN THE TREATMENT OF METASTATIC COLORECTAL-CANCER - REPLY
    BUDD, GT
    BUKOWSKI, RM
    MCCRACKEN, JD
    MACDONALD, JS
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) : 1492 - 1493
  • [10] Chronomodulated infusion of 5-fluorouracil, folinic acid and carboplatin in colorectal cancer: A pilot study
    Natoli, C
    Martino, MT
    Irtelli, L
    DOstilio, N
    Basilico, L
    Iacobelli, S
    ANTICANCER RESEARCH, 1995, 15 (6B) : 2841 - 2842